NCT06336382 is a clinical trial of Tau PET imaging scan in Late Onset Schizophrenia, sponsored by Jeremy Koppel.

Who is sponsoring NCT06336382?

NCT06336382 is sponsored by Jeremy Koppel.

What drugs are being tested in NCT06336382?

Interventions in NCT06336382: Tau PET imaging scan.

What condition does NCT06336382 study?

NCT06336382 studies Late Onset Schizophrenia, Delusional Disorder (Late Onset).

Is NCT06336382 still recruiting?

NCT06336382 is currently recruiting now. Last updated 29 September 2025.

Last reviewed 2025-09-29 · How we verify

NCT06336382

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tau Biomarkers in Late-onset Psychosis (LOP)

Recruiting now Last updated 29 September 2025

What this trial tests

trial testing Tau PET imaging scan in Late Onset Schizophrenia in 16 participants. Currently enrolling.

Timeline

16 February 2024

Primary endpoint
31 December 2026

30 June 2027

Quick facts

Lead sponsor	Jeremy Koppel
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	16
Start date	16 February 2024
Primary completion	31 December 2026
Estimated completion	30 June 2027
Sites	1 location across United States

Drugs / interventions tested

Tau PET imaging scan

Conditions studied

Late Onset Schizophrenia — all drugs for Late Onset Schizophrenia →
Delusional Disorder (Late Onset) — all drugs for Delusional Disorder (Late Onset) →

Sponsor

Jeremy Koppel

Who can join

Adults 65 to 85, any sex, with Late Onset Schizophrenia or Delusional Disorder (Late Onset). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Revisiting the therapeutic landscape of tauopathies: assessing the current pipeline and clinical trials.
Harris GA, Hirschfeld LR, Gonzalez MI, Pritchard MC, et al · · 2025 · cited 8× · PMID 40462159 · DOI 10.1186/s13195-025-01775-x

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06336382 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jeremy Koppel
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06336382.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing